How to Build a Commercialization Strategy for Biotech Companies
Written byNeta Kela, PhDFounder & Managing Partner
How to Build a Commercialization Strategy for Biotech Companies
For many biotech companies, commercialization feels like a distant milestone — something to figure out after the science works, after the clinical data reads out, after the regulatory approval comes through.
This is one of the most common and costly strategic mistakes in the industry.
The companies that successfully bring therapies to market are those that begin building their commercialization strategy early — often years before a product reaches patients. Commercialization is not a phase. It is a mindset that should inform decisions from preclinical development onward.
Why Early Commercialization Planning Matters
The Cost of Waiting
Biotech companies that delay commercialization planning until Phase 3 or later frequently encounter:
- Misaligned clinical endpoints that don't resonate with payers
- Pricing strategies that don't reflect the competitive landscape
- Manufacturing gaps that delay launch readiness
- Underfunded commercial teams scrambling to build capabilities under time pressure
A 6-month launch delay for a specialty therapy can represent tens of millions in lost revenue — and potentially missed market windows.
The Strategic Advantage of Starting Early
Companies that integrate commercial thinking from Phase 1 or Phase 2 gain critical advantages:
- Clinical trials designed with payer-relevant endpoints
- Clearer target product profiles that attract partners and investors
- Manufacturing and supply chain readiness aligned with launch timelines
- Stronger positioning in licensing and partnership discussions
The Five Pillars of Biotech Commercialization Strategy
1. Market Understanding and Competitive Intelligence
Before you can commercialize a therapy, you need a deep understanding of:
The disease landscape:
- How is the disease currently diagnosed and treated?
- What are the unmet needs from the perspective of patients, physicians, and payers?
- How large is the addressable patient population — and how is it evolving?
The competitive environment:
- What therapies are currently on the market or in late-stage development?
- What is the standard of care, and how entrenched is it?
- Where are the differentiation opportunities for your product?
Key action: Conduct a thorough competitive landscape analysis during Phase 1. Update it quarterly. The landscape will shift — and your strategy must shift with it.
2. Target Product Profile and Value Proposition
The Target Product Profile (TPP) is more than a regulatory document. It is the strategic blueprint that translates your science into commercial value.
A strong TPP should answer:
- What clinical benefit does this therapy deliver over existing options?
- What evidence will payers need to justify reimbursement?
- What is the optimal patient population — broad or targeted?
- What is the intended route of administration and treatment setting?
The value proposition translates the TPP into language that resonates with each stakeholder:
- For physicians: clinical efficacy, safety profile, ease of use
- For payers: cost-effectiveness, budget impact, real-world outcomes
- For patients: quality of life improvement, convenience, access
- For partners/investors: market size, differentiation, commercial potential
Key action: Develop your TPP collaboratively across R&D, regulatory, medical affairs, and commercial teams. Revisit it at every development milestone.
3. Pricing, Reimbursement, and Market Access Strategy
Pricing strategy is one of the most consequential decisions a biotech company will make — and it must be informed by market access realities in each target geography.
Key considerations:
Price positioning:
- What is the value-based price ceiling for your therapy?
- How does your pricing compare to standard of care and emerging competitors?
- What is the willingness to pay across different markets (US, EU, rest of world)?
Payer engagement:
- When should you begin engaging with payers and HTA bodies?
- What evidence gaps exist that could jeopardize reimbursement?
- Do you need a health economics and outcomes research (HEOR) strategy?
Market access planning:
- Which markets will you launch in first, and why?
- What is your launch sequencing strategy across geographies?
- How will reference pricing dynamics affect your global pricing architecture?
Key action: Begin payer advisory boards and early HTA engagement during Phase 2. Design your Phase 3 trials with payer-relevant endpoints and comparators.
4. Commercial Operations and Go-to-Market Model
For biotech companies, the go-to-market model decision is pivotal:
Build vs. Partner vs. Hybrid:
- Build your own commercial team: Maximum control, but capital-intensive. Best suited for focused launches in a single therapeutic area with a manageable prescriber base.
- Partner with a larger pharma company: Access to established infrastructure, but requires giving up economics and control. Best for broad market launches or global commercialization.
- Hybrid model: Retain commercialization rights in key markets (e.g., US) while partnering for others (e.g., EU, Asia). Increasingly common for mid-stage biotechs.
Key commercial capabilities to build or access:
- Medical affairs and KOL engagement
- Sales force (specialty or rare disease)
- Market access and payer relations
- Patient services and hub programs
- Distribution and supply chain management
Key action: Define your go-to-market model 18-24 months before anticipated approval. If building internally, begin hiring commercial leadership during Phase 3.
5. Launch Readiness and Execution
A successful launch requires meticulous preparation across multiple workstreams:
12-18 months pre-launch:
- Finalize pricing and contracting strategy
- Build payer dossiers and formulary submission packages
- Establish distribution and specialty pharmacy partnerships
- Develop medical education programs and KOL engagement plans
6-12 months pre-launch:
- Train and deploy sales team
- Launch disease awareness campaigns
- Finalize patient support programs
- Ensure manufacturing and supply chain readiness
At launch:
- Execute coordinated launch across all channels
- Monitor early adoption metrics and adjust messaging
- Engage with payers on coverage decisions
- Track patient access and time-to-therapy
Key action: Create a cross-functional launch readiness team with clear milestones, accountability, and regular governance reviews.
Common Mistakes Biotech Companies Make
1. Treating commercialization as a post-approval activity
By the time you have approval, it is too late to build a commercial organization from scratch. The best companies begin 2-3 years before launch.
2. Underestimating the complexity of market access
Especially in Europe, market access is not automatic after regulatory approval. Each country requires a dedicated pricing and reimbursement strategy.
3. Building clinical programs without commercial input
If your Phase 3 trial uses a comparator or endpoint that payers don't care about, your therapy may be approved but not reimbursed.
4. Ignoring the patient journey
Understanding how patients are diagnosed, referred, and treated is essential for designing effective commercial programs and patient support services.
5. Over-indexing on the US market
While the US offers the highest pricing, ignoring EU and rest-of-world markets leaves significant revenue on the table — and may limit partnership opportunities.
The Role of Strategic Advisory
Building a commercialization strategy requires expertise that spans regulatory science, market access, commercial operations, and business development.
For biotech companies — particularly those preparing for their first commercial launch — engaging experienced advisors can:
- Pressure-test assumptions and identify blind spots
- Provide frameworks proven across multiple therapeutic areas
- Build evidence that withstands partner, payer, and KOL scrutiny
- Accelerate decision-making at critical inflection points
The difference between a good therapy and a commercially successful therapy is often not the science — it is the strategy.
Conclusion
Commercialization is not the final chapter of drug development. It is a thread that should run through every stage — from target selection to market launch.
Biotech companies that embrace this mindset will design better trials, raise capital more effectively, attract stronger partners, and ultimately bring their therapies to more patients, faster.
The science creates the opportunity. The strategy captures it.
*At PXM, we work with biotech companies across development and commercial stages to build commercialization strategies that align science, development, and market reality. If you are preparing for your next milestone, request an expert review.*
How PXM Helps With This
Biotech Readiness Assessment
A 10 minute diagnostic of your regulatory, CMC, and partnering readiness.
CMC Strategy & Manufacturing Readiness
CMC roadmaps, CDMO selection, comparability strategy, and CMC submissions.
PXM Webinars
Live sessions on FDA strategy, regulatory readiness, and pharma partnering.
Related
Part of Capital, Licensing & M&A. Start from the pillar: For Investors & Pharma, Scout practice, Transact practice
The Delaware Flip: How European Biotechs Win US VC Funding
What a Delaware flip is, when a European biotech should do one, and what US VCs check in diligence. Includes a US-VC readiness checklist.
Biotech M&A Targets in 2026: Where Pharma Is Really Buying
Biotech M&A targets in 2026: oncology and immunology lead, CVRM fades, China licensing surges. Where buyers are spending and the red flags to check.
From UK to Global: A Commercialization Roadmap for British Biotech Companies
The UK is one of the world's strongest life science ecosystems — but for British biotech companies with global ambitions, moving from a UK-centric operation to a commercially successful international business requires deliberate strategy across regulatory, commercial, and partnership dimensions.
Get notified when we publish new funding and regulatory guides
Practical guidance on FDA and EMA strategy, CMC readiness, and non-dilutive funding — sent only when there is something worth reading.